-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kelun’s celecoxib capsules and afatinib maleate tablets have updated their review status, and the four types of generic listing applications for the two products have entered "under approval", which is expected to usher in good news in the near future.
Figure 1: Kelun's listing application under review
Source: Meinenet MED2.
Figure 2: Sales of Celecoxib Capsules
Source: Mi Nei.
According to the latest data from Minai.
Figure 3: Domestic pharmaceutical companies that have obtained approval for afatinib maleate tablets
Source: One-click search on Mi Nei.
Afatinib belongs to the second generation of EGFR-TKI, developed by Boehringer Ingelheim, entered the domestic market in 2017, and in 2020, the terminal sales of public medical institutions in China will exceed 400 million yuan.
Table 1: Generic drugs approved by Kelun and its subsidiaries since 2021 (statistics based on the date of approval)
Source: Meinenet MED2.
Since 2021, Kelun and its subsidiaries have been approved to market 6 generic drugs, all of which are registered in Category 3 and Category 4, which are deemed to be over-rated, and are distributed throughout the body with anti-infective drugs, anti-tumor and immunomodulators, and blood And the three major subcategories of hematopoietic system drugs.
